Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1251 - 1258 of 1258

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1551 - 1575 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Kyprolis for Multiple Myeloma (relapsed) – Details	pcodr_profund_carfilzomib_kyprolis_mm_rel.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_rec.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_cgr.pdf pcodr_carfilzomib_kyprolis_mm_rel_fn_egr.pdf pcodr_carfilzomib_kyprolis_mm_rel_in_rec.pdf pcodr_carfilzomib_kyprolis_mm_rel_fdk_amgen.pdf pcodr_carfilzomib_kyprolis_mm_rel_pagfdk.pdf pcodr_carfilzomib_kyprolis_mm_rel_ptfdk_mmc.pdf pcodr_carfilzomib_kyprolis_mm_rel_fdk_cln.pdf pcodr_carfilzomib_kyprolis_mm_rel_coi_mmc.pdf pcodr_carfilzomib_kyprolis_mm_rel_coi_cln.pdf	Apr 17, 2017	Reimbursement Review		Complete	PC0084-000
Avastin for Malignant Pleural Mesothelioma – Details		Apr 11, 2017	Reimbursement Review		Withdrawn	PC0100-000
Zykadia for Non-Small Cell Lung Cancer (Resubmission) – Details	pcodr_provfund_ceritinib_zykadia_nsclc_resub.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_rec.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_cgr.pdf pcodr_ceritinib_zykadia_nsclc_resub_fn_egr.pdf pcodr_ceritinib_zykadia_nsclc_resub_in_rec.pdf pcodr_ceritinib_zykadia_nsclc_resub_pagfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_fdk_novartis.pdf pcodr_ceritinib_zykadia_nsclc_resub_ptfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_clinfdk.pdf pcodr_ceritinib_zykadia_nsclc_resub_coi_lcc.pdf pcodr_ceritinib_zykadia_nsclc_resub_coi_clin.pdf	Apr 5, 2017	Reimbursement Review		Complete	PC0094-000
Buprenorphine Implant for the Treatment of Opioid Use Disorder		Mar 21, 2017	Horizon Scan		Completed	EH0044-000
travoprost ophthalmic solution	cdr_SR0516_Izba.pdf SR0516_Izba_complete_Oct-30-17.pdf SR0516_Izba_CL_Report.pdf SR0516_Izba_PE_Report.pdf	Jan 31, 2017	Reimbursement Review		Complete	SR0516-000
Venclexta for Chronic Lymphocytic Leukemia (with 17p deletion) – Details	pcodr_venetoclax_venclexta_cll_17pdel_in_cgr.pdf pcodr_venetoclax_venclexta_cll_17pdel_in_egr.pdf pcodr_venetoclax_venclexta_cll_17pdel_in_rec.pdf	Jan 10, 2017	Reimbursement Review		Withdrawn	PC0087-000
Etanercept	cdr_SE0513_TBC.pdf SE0513_complete_Erelzi_Jul_28_17_e.pdf SE0513_Erelzi_SEB_Report.pdf SE0513_Erelzi_PI_Submissions.pdf	Jan 5, 2017	Reimbursement Review		Complete	SE0513-000
Brexpiprazole	cdr_SR0514_TBC.pdf SR0514_Rexulti_complete_Nov_24_17.pdf SR0514_Rexulti_CL_Report.pdf SR0514_Rexulti_PE_Report.pdf SR0514_Rexulti_PI_Submissions.pdf	Jan 4, 2017	Reimbursement Review		Complete	SR0514-000
abobotulinumtoxinA	cdr_SR0512_Dysport_Therapeutic.pdf SR0512_complete_Dysport_Therapeutic_Jul_28_17_e.pdf SR0512_Dysport_Therapeutic_CL_Report_e.pdf SR0512_Dysport_Therapeutic_PE_Report_e.pdf SR0512_Dysport_Therapeutic_PI_Submissions.pdf	Jan 3, 2017	Reimbursement Review		Complete	SR0512-000
Darzalex for Multiple Myeloma – Details	pcodr_daratumumab_darzalex_mm_fn_rec.pdf pcodr_daratumumab_darzalex_mm_fn_cgr.pdf pcodr_daratumumab_darzalex_mm_fn_egr.pdf pcodr_daratumumab_darzalex_mm_in_rec.pdf pcodr_daratumumab_darzalex_mm_pagfdk.pdf pcodr_daratumumab_darzalex_mm_fdk_janssen.pdf pcodr_daratumumab_darzalex_mm_fdk_mc.pdf pcodr_daratumumab_darzalex_mm_fdk_clinician.pdf pcodr_daratumumab_darzalex_mm_coi_mc.pdf pcodr_daratumumab_darzalex_mm_coi_clinician.pdf	Dec 16, 2016	Reimbursement Review		Complete	PC0079-000
Afinitor for Neuroendocrine tumors of Gastrointestinal or Lung origin – Details	pcodr_profund_everolimus_afinitor_net-gil.pdf pcodr_everolimus_afinitor_net-gil_fn_rec.pdf pcodr_everolimus_afinitor_net-gil_fn_cgr.pdf pcodr_everolimus_afinitor_net-gil_fn_egr.pdf pcodr_everolimus_afinitor_net-gil_in_rec.pdf pcodr_everolimus_afinitor_net-gil_pagfdk.pdf pcodr_everolimus_afinitor_net-gil_fdk_novartis.pdf pcodr_everolimus_afinitor_net-gil_fdk_cnets.pdf pcodr_everolimus_afinitor_net-gil_coi_cnets.pdf	Dec 16, 2016	Reimbursement Review		Complete	PC0083-000
Eliglustat	cdr_SR0511_Cerdelga.pdf SR0511_complete_Cerdelga_Jul_28_17_e.pdf SR0511_Cerdelga_CL_Report_e.pdf SR0511_Cerdelga_PE_Report_e.pdf SR0511_Cerdelga_PI_Submissions.pdf	Dec 15, 2016	Reimbursement Review		Complete	SR0511-000
Glatiramer acetate	cdr_SE0510_Glatect.pdf SE0510_complete_Glatect-Jul-27-e.pdf SE0510_Glatect _PI_Submissions.pdf SE0510_Glatect_SENB_Complex_Drug_Submission_Report.pdf	Dec 15, 2016	Reimbursement Review		Complete	SE0510-000
Single Drug Technology Assessment Processes Across Health Technology Assessment Organizations		Dec 9, 2016	Health Technology Review	Environmental Scan	Completed	ES0293-000
Ibrance for Advanced Breast Cancer Resubmission – Details	pcodr_profund_10093_palbociclib_ibrance_abc_resub.pdf pcodr_palbociclib_ibrance_resub_abc_fn_rec.pdf pcodr_palbociclib_ibrance_resub_abc_fn_cgr.pdf pcodr_palbociclib_ibrance_resub_abc_fn_egr.pdf pcodr_palbociclib_ibrance_resub_abc_in_rec.pdf pcodr_palbociclib_ibrance_resub_abc_pagfdk.pdf pcodr_palbociclib_ibrance_resub_abc_fdk_pfizer.pdf pcodr_palbociclib_ibrance_resub_abc_ptfdk_rethink.pdf pcodr_palbociclib_ibrance_resub_abc_ptfdk_cbcn.pdf pcodr_palbociclib_ibrance_resub_abc_coi_cbcn-rethink.pdf pcodr_palbociclib_ibrance_resub_abc_coi_clinician.pdf	Dec 6, 2016	Reimbursement Review		Complete	PC0093-000
Onivyde for Metastatic Pancreatic Cancer (Closed)		Dec 2, 2016	Reimbursement Review		Cancelled	PC0096-000
Obeticholic Acid	cdr_SR0509_TBC.pdf SR0509_complete_Ocaliva_Jul_27_17_e.pdf SR0509_Ocaliva_CL_Report_e.pdf SR0509_Ocaliva_PE_Report_e.pdf SR0509 Ocaliva_PI_Submissions.pdf	Nov 24, 2016	Reimbursement Review		Complete	SR0509-000
Keytruda for Non-Small Cell Lung Cancer (Second Line or Beyond) – Details	pcodr_provfund_pembrolizumab_keytruda_nsclc_2lnbeyond.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_cgr.pdf pcodr_pembrolizumab_keytruda_nsclc_fn_egr.pdf pcodr_pembrolizumab_keytruda_nsclc_in_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_pagfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_fdk_merck.pdf pcodr_pembrolizumab_keytruda_nsclc_ptfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_coi_lcc.pdf pcodr_pembrolizumab_keytruda_nsclc_fdk_clinician.pdf pcodr_pembrolizumab_keytruda_nsclc_coi_clinician.pdf	Nov 18, 2016	Reimbursement Review		Complete	PC0077-000
Imbruvica for Chronic Lymphocytic Leukemia (previously untreated) – Details	pcodr-provfund_ibrutinib_imbruvica-cll-sll-preun.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_rec.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_cgr.pdf pcodr_ibrutinib_imbruvica_cll-sll_fn_egr.pdf pcodr_ibrutinib_imbruvica_cll-sll_in_rec.pdf pcodr_ibrutinib_imbruvica_cll-sll_pagfdk.pdf pcodr_ibrutinib_imbruvica_cll-sll_fdk_janssen.pdf pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_cllpag.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_cllpag.pdf pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_lc.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_lc.pdf pcodr_ibrutinib_imbruvica_cll-sll_coi_clinician.pdf	Nov 18, 2016	Reimbursement Review		Complete	PC0085-000
Imbruvica for Waldenström’s Macroglobulinemia - Details	pcodr-provfund_ibrutinib_imbruvica-wm.pdf pcodr_ibrutinib_imbruvica_wm_fn_rec.pdf pcodr_ibrutinib_imbruvica_wm_fn_cgr.pdf pcodr_ibrutinib_imbruvica_wm_fn_egr.pdf pcodr_ibrutinib_imbruvica_wm_in_rec.pdf pcodr_ibrutinib_imbruvica_wm_pagfdk.pdf pcodr_ibrutinib_imbruvica_wm_fdk_janssen.pdf pcodr_ibrutinib_imbruvica_wm_ptfdk_cord.pdf pcodr_ibrutinib_imbruvica_wm_ptfdk_lc.pdf pcodr_ibrutinib_imbruvica_wm_coi_lc_cord.pdf	Nov 18, 2016	Reimbursement Review		Complete	PC0082-000
Kyprolis (with lenalidomide) for Multiple Myeloma – Details	pcodr_profund_10067carfilzomib_kyprolis_lenalidomide_mm.pdf pcodr_carfilzomib_kyprolis_mm_fn_rec.pdf pcodr_carfilzomib_kyprolis_mm_fn_cgr.pdf pcodr_carfilzomib_kyprolis_mm_fn_egr.pdf pcodr_carfilzomib_kyprolis_mm_in_rec.pdf pcodr_carfilzomib_kyprolis_mm_pagfdk.pdf pcodr_carfilzomib_kyprolis_mm_fdk_amgen.pdf pcodr_carfilzomib_kyprolis_mm_coi_mc.pdf	Nov 11, 2016	Reimbursement Review		Complete	PC0067-000
emtricitabine/rilpivirine/ tenofovir alafenamide	cdr_SR0507_TBC.pdf SR0507_complete_Odefsey- May-25-17_e.pdf SR0507_Odefsey_Combined_Report.pdf SR0507_Odefsey_PI_Submissions.pdf	Oct 27, 2016	Reimbursement Review		Complete	SR0507-000
Daclizumab beta	cdr_SR0508_Zinbryta.pdf SR0508_compelte_Zinbryta_Jun-22-17_e.pdf SR0508_Zinbryta_CL_Report.pdf SR0508_Zinbryta_PE_Report.pdf SR0508_Zinbryta_PI_Submissions.pdf	Oct 18, 2016	Reimbursement Review		Complete	SR0508-000
Lynparza for Ovarian Cancer (2nd line) – Details	pcodr_provfund_olaparib_lynparza_oc.pdf pcodr_olaparib_lynparza_oc_fn_rec.pdf pcodr_olaparib_lynparza_oc_fn_cgr.pdf pcodr_olaparib_lynparza_oc_fn_egr.pdf pcodr_olaparib_lynparza_oc_in_rec.pdf pcodr_olaparib_lynparza_oc_pagfdk.pdf pcodr_olaparib_lynparza_oc_fdk_azc.pdf pcodr_olaparib_lynparza_oc_ptfdk.pdf pcodr_olaparib_lynparza_oc_coi_occ.pdf pcodr_olaparib_lynparza_oc_fdk_clinician.pdf pcodr_olaparib_lynparza_oc_coi_clinician.pdf	Oct 17, 2016	Reimbursement Review		Complete	PC0081-000
Zydelig for Follicular Lymphoma – Details	pcodr-provfund_idelalisib-zydelig-fl.pdf pcodr_idelalisib_zydelig_fl_fn_rec.pdf pcodr_idelalisib_zydelig_fl_fn_cgr.pdf pcodr_idelalisib_zydelig_fl_fn_egr.pdf pcodr_idelalisib_zydelig_fl_in_rec.pdf pcodr_idelalisib_zydelig_fl_pagfdk.pdf pcodr_idelalisib_zydelig_fl_fdk_gilead.pdf pcodr_idelalisib_zydelig_fl_ptfdk_lc.pdf pcodr_idelalisib_zydelig_fl_coi_lc.pdf	Oct 17, 2016	Reimbursement Review		Complete	PC0075-000